WESTMINSTER, Colo.,
May 16, 2012 /PRNewswire/ --
GeneThera, Inc. (OTCQB: GTHR) announced today that Applied
Genetics, GeneThera's majority owned subsidiary, signed a research
and test validation agreement with Universidad National Autonoma de
Mexico (UNAM). Scope of the
agreement is to validate GeneThera proprietary Johne's disease (JD)
HerdCheck Field Collection System (FCS) Molecular Assay in
Mexico. Dr. Tony Milici, interim president of Applied
Genetics and CEO of GeneThera, stated, "This agreement is another
major milestone in establishing GeneThera and Applied Genetics'
leadership in the field of Johne's disease molecular testing.
UNAM's support is of fundamental importance to speed up the
validation process of GeneThera's Johne's disease molecular
testing, which will lead to JD test approval by the Mexican
Government."
Dr. Gilberto Chaves Griz,
Professor of Veterinary Pathology, in the Department of Veterinary
medicine at UNAM and Director of the Johne's Disease Center, who is
one of the world's most renowned expert in the field of Johne's
disease declared, "We are very pleased to partner with Applied
Genetics and GeneThera to work on this project. It is extremely
critical that we can diagnose JD in Mexico using the most advanced technology
available. It is also of paramount importance to establish a
Johne's disease program at the national level. Mexico has one of the largest cows, goat and
sheep populations in Northern and Central
America, yet no data exists to the extent of Johne's
infection in these animals. It is our firm intention to establish a
National Testing Program for Johne's Disease in Mexico with the help of Applied Genetics and
GeneThera's state of the art technology." UNAM is the largest
University in Mexico. Applied
Genetics is a molecular diagnostic company that focuses on
commercializing molecular testing for Johne's disease in
Mexico.
Johne's disease is a global devastating and incurable disease of
dairy cows, sheep and goats caused by a bacterium called
Mycobacterium Paratuberculosis sub. Avium, (MAP). Dairy
products, contaminated with MAP, are the vehicles by which the
infection spreads in the human intestine triggering the onset of
Crohn's disease. Applied Genetics employs the use of GeneThera
HerdCheck to test and control the spread of Johne's disease in
Mexico. HerdCheck is a proprietary molecular diagnostic
system based on the use of high throughput robotics and Real time
PCR.
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in
Westminster, Colorado. The
Company's proprietary diagnostic solution is based on a genetic
expression system (GES) and Johne's disease management system,
HERDCHECK, designed to function on a highly automated Fluorogenic
PCR platform. This platform enables GeneThera to offer tests that
are presently not available from other technologies. The GES and
HERDCHECK systems are designed for a host of individual diseases,
the current priority being Johne's disease. For more information,
contact Dr. Tony Milici at 720
439-3011.
This press release contains forward-looking statements, which
are made pursuant to the Safe-Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "intends,"
"believes," and similar expressions reflecting something other than
historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such
statements. These forward-looking statements involve a number of
risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to
secure additional sources of finance, the ability to reduce
operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual
results that the Company achieves may differ materially from any
forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
http://www.genethera.net
SOURCE GeneThera, Inc.
